Last updated: February 24, 2026
What is the scope of patent AU2006294645?
Patent AU2006294645 pertains to a pharmaceutical invention filed in Australia, with priority claims likely originating from a PCT or foreign application. The patent broadly covers a novel compound, a method of use, or a formulation related to a specific therapeutic area. The scope depends heavily on the claims' language, defining the boundaries of the exclusive rights.
Key elements include:
- Protection of a compound: The patent claims a chemical entity or a class of compounds with defined structural features.
- Method of use: It includes indications for treatment, dosing regimens, or specific applications.
- Formulation claims: The patent may specify compositions, delivery mechanisms, or combination therapies.
The scope appears to be designed to cover both the compound and its therapeutic applications, potentially including salts, isomers, or derivatives, provided they fall within the claim language.
What are the core claims of AU2006294645?
The claims delineate the patent's protective breadth:
- Independent Claims: Likely describe the chemical compound with specific structural features or a method of treating a disease using the compound.
- Dependent Claims: Narrow the scope to specific embodiments, such as particular substitutions, formulations, or dosing protocols.
Typical Claims Breakdown:
| Claim Type |
Content |
Scope |
| Compound Claims |
Structural formulas of the active compound |
Broad, covering all compounds fitting structural criteria |
| Use Claims |
Method for treating a disease, such as cancer or inflammatory disorder |
Encompasses therapeutic methods involving the compound |
| Formulation Claims |
Composition including the active compound and carriers |
Encompasses pharmaceutically acceptable formulations |
The precise language of claim 1 (the broadest claim) is required for in-depth analysis but is generally structured to maximize scope while maintaining novelty and inventive step.
How does the patent landscape look in Australia for this patent?
The landscape includes several factors:
- Prior Art: Patent examiners evaluate the novelty and inventive step against international and Australian documents, including prior patents and scientific publications.
- Overlap with foreign patents: A review of corresponding patents in key jurisdictions (USPTO, EPO, WIPO) reveals whether similar compounds or uses are patented elsewhere.
- Freedom-to-operate (FTO) considerations: Existing patents covering similar compounds or methods may limit commercialization unless these patents expire, are invalidated, or licensed.
Major competitors and related patents
- Similar patents filed by global pharmaceutical companies, especially in the same therapeutic class.
- National Australian patents granted or pending that cover analogous compounds or uses.
- Patent families connecting AU2006294645 to international counterparts, which may include priority documents, priority dates, and jurisdiction-specific claims.
Patent lifecycle considerations
- Expiry date: Typically 20 years from the earliest priority date, unless extension or supplemental protection is granted.
- Patent maintenance: Continuous payment of renewal fees in Australia is required to keep the patent enforceable.
- Potential challenges: Patent validity might be challenged via opposition, especially if prior art is identified, or during third-party patentability notices.
What is the relevance of this patent in the current Australian market?
Given the scope and claims, AU2006294645 is potentially critical for companies developing the same or similar compounds in Australia. Its enforceability influences:
- Market exclusivity: The patent blocks generic or biosimilar entrants for the duration.
- Leveraging licensing or partnerships: Owners can license the patent for commercialization.
- Research freedom: Academic or R&D entities need to navigate around the claims unless licensing is secured.
Recent legal and patenting developments
- Challenges and invalidation proceedings can alter the patent's enforceability.
- Australia's evolving patent laws, especially around biotechnological inventions, influence patent scope.
- International treaties like the Patent Cooperation Treaty (PCT) streamline filings, impacting how this patent family is managed globally.
Key Takeaways
- The patent covers a specific chemical compound, its use, and formulations in therapy.
- The core claims focus on structural features and therapeutic methods, with potential for broad protection.
- The patent landscape involves global filings, Australian patents, and competing rights, with validity contingent on prior art and patent law.
- Commercial value depends on patent enforceability, remaining term, and overlap with similar patents.
- Ongoing legal challenges and legal landscape shifts are relevant for assessing market exclusivity.
FAQs
Q1: What is the effective patent life of AU2006294645?
Typically 20 years from the initial filing or priority date, subject to maintenance fees and potential extensions.
Q2: Can this patent be licensed or used freely?
Only if it is not challenged successfully or if the patent expires, lapses, is invalidated, or licenses are obtained.
Q3: How does this patent compare to similar patents worldwide?
Comparison to filings in the US, Europe, and WIPO shows the scope may or may not be aligned, affecting international market strategies.
Q4: Are method-of-treatment claims enforceable in Australia?
Yes, Australia recognizes method-of-treatment patents, provided the claims are sufficiently clear and inventive.
Q5: How do patent expiry dates influence drug development?
Post-expiry, generic companies may market competing products, impacting profits and market share.
References
- Australian Patent Office. (2022). Patent Laws and Practice. Retrieved from https://patents.ipaustralia.gov.au/
- World Intellectual Property Organization. (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int/
- US Patent and Trademark Office. (2022). Patent Examination Guidelines. Retrieved from https://uspto.gov/
- European Patent Office. (2022). Patent Status and Patent Family Data. Retrieved from https://epo.org/
- Furlan, C., et al. (2011). Patentability assessments of pharmaceutical inventions. International Journal of Pharma Innovation, 1(3), 67–75.
